INDOCO REMEDIES LTD

1

Company Profile

A fast growing, fully integrated, research oriented pharmaceutical company with a Global presence.

Strong domestic marketing setup with PAN India presence.

Workforce of over 4000- 200 R&D scientists -1800 Field staff

Revenues in FY 2010-11 Rs. 4800 mn. (US$ 100 mn) (Domestic & International contribution 65 % & 35% respectively)

Listed on Stock Exchanges in India

2

Our Infrastructure

Corporate Office at Santacruz (E), Mumbai

9 Manufacturing Facilities 5 – FDFs 4 – APIs

R&D Centre at Navi Mumbai

35 Depots & Branches

3

Mfg. Facilities for FDFs

LOCATIONDOSAGE

FORMAPPROVALS

GOA ITABLETS,

CREAMS & OINTMENTS

EU - GMP, Australia, South Africa

GOA IISTERILE

PRODUCTSEU - GMP, USA,

South Africa

GOA III TABLETS Awaited

WALUJ TABLETS Emerging Markets

BADDITABLETS,

LIQUID ORALS & TOOTHPASTES

EU – GMP

4

API Facilities

Kilo Scale: Navi Mumbai Reaction Systems: 16 to 500 L Total Reactor Volume: 1 cubic meters Temperatures range: -55 to + 150

celsius

Multi-ton : Patalganga (I) Reactor Capacity: 500 to 5000 L

Mid-Volume : Patalganga (II) Reactor Capacity: 500 to 2000 L

Intermediates : Rabale Reactor Capacity: 500 to 3000 L Total Reactor Volume: 50 cubic meters

5

Research & Development

US $ 10 million Investment

Spread over an area of 100,000 square feet and employs over 200 scientists and technical personnel

34 Patents filed

R&D activities include: - Chemical synthesis of APIs and Intermediates with non-infringing processes - Formulation Development including NDDS and new technology platforms - Analytical Research - Regulatory services 6

Branded

Generics APIs

Regulated Markets

- Alliances - Customer

Network Emerging

Markets - Distributor

Model

Covers 80 countries Licensing out CRAMS Branded Generics

18 Therapeutic

Segments 160 Brands 8 Marketing

Divisions

Indian Business

Business Model

International

Business

Vertically Integrated

7

Indian Business

INDOCO – GP, CP, Gynaec

SPADE – GP, CP, Paediatrician, ENT

WARREN –Dental

EXCEL – Opthal

SPERA – GP, Gynaec, Paediatrician

ETERNA – CPs, Orthos, Gastro

XTEND – GPs in Extra Urban Towns

CND – Lifestyle/Cardio & Diabetology Ranked 27th by CMARC in Rx Ranking (Dec’ 2011) Ranked 30th by AWACS in SSA Audit (Jan’ 2012)

8

Brand Therapeutic Areas Rank Market Share

HOMIDE Ophthalmic 1 91.70%CYCLOPAM Anti-Spasmodic 1 54.30%CITAL Urinary Alkalizer 1 30.80%SENSODENT-K Desensitizing Toothpaste 1 7.30%SENSOFORM Desensitizing Toothpaste 1 5.30%       SCABEX Scabies Skin Cream 2 23.80%CLOBEN-G Antifungal Skin Cream 2 11.90%CARMICIDE Anti-Flatulent 2 17.00%ATM Anti-Infectiver 2 9.30%       VEPAN Anti-Infective 3 16.20%FEBREX PLUS Anti-Cold 3 9.20%       KARVOL PLUS Nasal Decongestant 4 6.30%NOSIC Anti-Emetic 4 4.70%       HEMSYL Gynaec 5 10.30%GLYCHEK-M Anti-Diabetic 5 6.90%TUSPEL PX Cough Syrup 5 4.10%OXIPOD Anti-Infective 5 3.60%

Few Brands which occupy leadership position (among top 5)

9

Growth Drivers (Domestic Business)

• Growing middle class population, increasing income levels, rapid urbanization, demand for quality healthcare services & changing lifestyle

• Focus in high potential territories such as tier-III towns and rural areas

• Product introductions in newer segments and therapies

• Intensive Pan – India coverage of the Medical Fraternity through various marketing divisions

• Thrust area for the Company

10

Regulated Markets

International Business

Emerging Markets

11

Growth Drivers (International Business)

• Strong relationship with Watson Pharmaceuticals Inc., USA

• Multi-product, Multi-territory alliance with Aspen Pharmacare, SA and extended to Sigma, Australia (Aspen’s acquisition)

• Alliance with DSM, a € 9 billion company, for marketing & distribution of APIs

• NDDS and new technology platforms

• New manufacturing facility at Goa to cater to the growing demand for supplies

• Registration of own Dossiers and Out-licensing of MA’s in Regulated Markets

12

(Rs. In Lacs)

Sr.No. Particulars Quarter ended

31.12.2011 (Unaudited)

Quarter ended 30.09.2011

(Unaudited)

Quarter ended 31.12.2010

(Unaudited)

Nine months ended

31.12.2011 (Unaudited)

Nine months ended

31.12.2010 (Unaudited)

Year ended 31.03.2011 (Audited)

1 Net Sales / Income from Operations 14,152 14,474 11,431 41,181 35,803 47,847

(b) Other Operating income 106 266 116 523 548 795

Total (a+b) 14,258 14,740 11,547 41,704 36,351 48,642

2 Expenditure : 13,162 13,140 10,440 37,540 31,910 42,748

3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)

1,096 1,600 1,107 4,164 4,441 5,894

4 Other Income - 5 2 5 3 5

5 Profit before Interest and Exceptional Items (3+4) 1,096 1,605 1,109 4,169 4,444 5,899

6 Interest 180 144 59 412 177 240

7 Profit after Interest but before Exceptional Items (5-6)

916 1,461 1,050 3,757 4,267 5,659

8 Exceptional Items - - - - - -

9 Profit from Ordinary Activities before tax (7+8) 916 1,461 1,050 3,757 4,267 5,659

10 Tax Expenses 90 80 169 376 378 547

11 Net Profit from Ordinary Activities after tax (9-10) 826 1,381 881 3,381 3,889 5,112

12 Extraordinary Items - - - - - -

13 Net Profit for the period (11-12) 826 1,381 881 3,381 3,889 5,112

14 Paid up Equi ty Share Capi ta l (Face va lue Rs .10/- each) 1,228.67 1,228.67 1,228.67 1,228.67 1,228.67 1,228.67

15 Reserves excluding Reva luation Reserves - - 33,791

16 Earning Per Share (EPS) - Not Annualised - Rs.

(a) Basic and diluted EPS before Extraordinary Items 6.72 11.24 7.17 27.52 31.65 41.60

(b) Basic and diluted EPS after Extraordinary Items 6.72 11.24 7.17 27.52 31.65 41.60

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2011

13

Thank You….. 14